JP2024507367A - ムスカリン受容体活性化によって改善される障害を処置するための方法 - Google Patents

ムスカリン受容体活性化によって改善される障害を処置するための方法 Download PDF

Info

Publication number
JP2024507367A
JP2024507367A JP2023550610A JP2023550610A JP2024507367A JP 2024507367 A JP2024507367 A JP 2024507367A JP 2023550610 A JP2023550610 A JP 2023550610A JP 2023550610 A JP2023550610 A JP 2023550610A JP 2024507367 A JP2024507367 A JP 2024507367A
Authority
JP
Japan
Prior art keywords
xanomeline
salt
trospium
patient
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023550610A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024507367A5 (enExample
Inventor
ミラー アンドリュー
ブランナン スティーヴン
カウル インダルジット
エヌ． マーカス ロナウド
エス． スモール デイヴィッド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Karuna Therapeutics Inc
Original Assignee
Karuna Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karuna Therapeutics Inc filed Critical Karuna Therapeutics Inc
Publication of JP2024507367A publication Critical patent/JP2024507367A/ja
Publication of JP2024507367A5 publication Critical patent/JP2024507367A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2023550610A 2021-02-24 2022-02-23 ムスカリン受容体活性化によって改善される障害を処置するための方法 Pending JP2024507367A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163153095P 2021-02-24 2021-02-24
US63/153,095 2021-02-24
US202163213998P 2021-06-23 2021-06-23
US63/213,998 2021-06-23
PCT/US2022/017485 WO2022182733A1 (en) 2021-02-24 2022-02-23 Methods for treating disorders ameliorated by muscarinic receptor activation

Publications (2)

Publication Number Publication Date
JP2024507367A true JP2024507367A (ja) 2024-02-19
JP2024507367A5 JP2024507367A5 (enExample) 2025-03-03

Family

ID=83048440

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023550610A Pending JP2024507367A (ja) 2021-02-24 2022-02-23 ムスカリン受容体活性化によって改善される障害を処置するための方法

Country Status (9)

Country Link
US (1) US20240156802A1 (enExample)
EP (1) EP4297732A4 (enExample)
JP (1) JP2024507367A (enExample)
AU (1) AU2022226157A1 (enExample)
BR (1) BR112023017019A2 (enExample)
CA (1) CA3209262A1 (enExample)
IL (1) IL305412A (enExample)
TW (1) TW202332443A (enExample)
WO (1) WO2022182733A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3856182T (pt) 2018-09-28 2026-03-10 Karuna Therapeutics Inc Composições e métodos para o tratamento de perturbações melhoradas pela ativação dos recetores muscarínicos
EP4091607A1 (en) * 2021-05-18 2022-11-23 Karuna Therapeutics, Inc. Methods for treating central nervous system disorders with muscarinic receptor activator xanomeline and antipsychotics
US12269818B2 (en) 2023-04-24 2025-04-08 Terran Biosciences Inc. Analogs of xanomeline
WO2026064593A1 (en) * 2024-09-20 2026-03-26 Karuna Therapeutics, Inc. Method and compositions relating to the treatment of neuro-degenerative and psychiatric diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020069301A1 (en) * 2018-09-28 2020-04-02 Karuna Therapeutics, Inc. Compositions and methods for treating disorders ameliorated by muscarnic receptor activation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2200610T3 (enExample) * 2007-09-21 2018-06-09
JP2023503056A (ja) * 2019-11-18 2023-01-26 カルナ セラピューティックス，インコーポレイテッド ムスカリン受容体活性化によって改善される障害を処置するための組成物及び方法
US20220370454A1 (en) * 2021-05-18 2022-11-24 Karuna Therapeutics, Inc. Methods for treating central nervous system disorders with muscarinic receptor activation and antipsychotics

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020069301A1 (en) * 2018-09-28 2020-04-02 Karuna Therapeutics, Inc. Compositions and methods for treating disorders ameliorated by muscarnic receptor activation

Also Published As

Publication number Publication date
WO2022182733A1 (en) 2022-09-01
EP4297732A1 (en) 2024-01-03
EP4297732A4 (en) 2025-03-26
IL305412A (en) 2023-10-01
BR112023017019A2 (pt) 2023-11-07
US20240156802A1 (en) 2024-05-16
AU2022226157A1 (en) 2023-09-14
TW202332443A (zh) 2023-08-16
CA3209262A1 (en) 2022-09-01

Similar Documents

Publication Publication Date Title
US12558317B2 (en) Compositions and methods for treating disorders ameliorated by muscarinic receptor activation
IL289974B (en) Methods and processes for non-invasive evaluation of genetic variations
US20240156802A1 (en) Methods for treating disorders ameliorated by muscarinic receptor activation
US20210145804A1 (en) Compositions and methods for treating disorders ameliorated by muscarinic receptor activation
CN115667235B (zh) 用于治疗由毒蕈碱受体激活所缓解的障碍的组合物和方法
CN117136048A (zh) 用于治疗由毒蕈碱受体激活所缓解的障碍的方法
HK40044922A (en) Compositions and methods for treating disorders ameliorated by muscarnic receptor activation

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20241211

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250219

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250219

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260303

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260529